首页> 外文期刊>Endocrine journal >Prognosis of primary aldosteronism in Japan: results from a nationwide epidemiological study
【24h】

Prognosis of primary aldosteronism in Japan: results from a nationwide epidemiological study

机译:日本原发性醛固酮增多症的预后:一项全国流行病学研究的结果

获取原文
获取原文并翻译 | 示例
           

摘要

The Research Committee of Disorders of Adrenal Hormones, Japan, undertook a nationwide epidemiological study of primary aldosteronism (PA). The present study was undertaken as a part of this study to reveal the relationship between type of treatment and the prognosis of PA. In the primary survey, 4161 patients with PA during the period January 1,2003-December 31, 2007 were reported from 3252 departments of internal medicine, pediatrics and urology. In the secondary survey, a questionnaire that requested detailed clinical information on individual patients was sent to those departments reporting patients in the primary survey. In total, data on 1706 patients with PA were available in the present study. Among patients with bilateral or unilateral aldosterone-producing adenoma, after adjustment for age at which prognosis was examined, sex, surgical treatment and medical treatment, surgical treatment was significantly associated with amelioration of hypertension (adjusted odds ratio [OR]: 0.47 [95% confidence interval (CI): 0.29-0.77]) and hypokalemia (adjusted OR: 0.17 [95% CI: 0.11-0.29]). No significant relationship was observed between medical treatment and such prognosis in this group of patients. Among patients with bilateral or unilateral adrenal hyperplasia, surgical, but not medical, treatment was significantly associated with amelioration ofhypokalemia (adjusted OR: 0.23 [95% CI: 0.06-0.74]), while there was no relationship between surgical or medical treatment and the prognosis of hypertension. In conclusion, surgery offered a better prognosis of PA than medication with regards to hypertension and hypokalemia, with the limitation that a new anti-aldosterone drug, eplerenone, was not available during the study period.
机译:日本肾上腺激素紊乱研究委员会对原发性醛固酮增多症(PA)进行了全国性的流行病学研究。本研究是本研究的一部分,旨在揭示治疗类型与PA预后之间的关系。在初步调查中,从3252内科,儿科和泌尿科报告了2003年1月1日至2007年12月31日期间的4161例PA患者。在第二次调查中,向各部门报告了要求对个别患者提供详细临床信息的调查问卷,这些患者在主要调查中报告了患者。总体而言,本研究可获得有关1706例PA患者的数据。在患有双侧或单侧醛固酮生成腺瘤的患者中,在调整了检查预后的年龄,性别,手术治疗和药物治疗后,手术治疗与高血压的改善显着相关(校正后的优势比[OR]:0.47 [95%]置信区间(CI):0.29-0.77]和低钾血症(校正后的OR:0.17 [95%CI:0.11-0.29])。在这一组患者中,药物治疗与此类预后之间未发现显着相关性。在双侧或单侧肾上腺增生的患者中,手术而非药物治疗与低钾血症的改善显着相关(校正OR:0.23 [95%CI:0.06-0.74]),而手术或药物治疗与低血钾没有关系。高血压的预后。总之,就高血压和低血钾症而言,外科手术提供的PA预后优于药物治疗,其局限性在于在研究期间尚无新的抗醛固酮药物依普利农。

著录项

  • 来源
    《Endocrine journal》 |2014年第1期|35-40|共6页
  • 作者单位

    Department of Preventive Medicine and Public Health, Faculty of Medicine, Fukuoka University, Fukuoka 814-0180, Japan;

    Department of Preventive Medicine and Public Health, Faculty of Medicine, Fukuoka University, Fukuoka 814-0180, Japan;

    Endocrinology and Diabetes Center, Yokohama Rosai Hospital, Yokohama 222-0036, Japan;

    Department of Endocrinology, Metabolism and Hypertension, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan;

    Department of Medicine and Bioregulatory Sciences, Graduate School of Medical Science, Kyushu University. Fukuoka 812-8582, Japan;

    Department of Pathology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan;

    Division of Endocrinology and Hypertension, Department of Internal Medicine, Graduate School of Medical Science, Kanazawa University, Kanazawa 920-8640, Japan;

    Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Yuhu 879-5593, Japan;

    Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan;

    Division of Nephrology, Endocrinology and Vascular Medicine, Department of Medicine, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan;

    Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Maebashi 371-8511, Japan;

    Department of Internal Medicine, Toho University School of Medicine, Tokyo 143-0015, Japan;

    Division of Metabolism and Endocrinology, Department of Internal Medicine, St. Marianna University School of Medicine Yokohama City Seibu Hospital, Yokohama 241-0811, Japan;

    Health Care Center, Kochi University, Kochi 780-8520, Japan;

    Department of Rheumatology and Allergy, Institute of Medical Science, The University of Tokyo, Tokyo 108-8039, Japan;

    Department of Pediatrics, Asahikawa Medical University, Asahikawa 078-8510, Japan;

    Department of Pediatrics, Asahikawa Medical University, Asahikawa 078-8510, Japan;

    Department of Pediatrics, Keio University School of Medicine, Tokyo 160-8582, Japan;

    Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo 157-8535, Japan;

    Department of Pediatrics, Hokkaido University School of Medicine, Sapporo 060-8635, Japan;

    Department of Endocrinology and Diabetes Mellitus, Faculty of Medicine, Fukuoka University, Fukuoka 814-0180, Japan;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    Nationwide epidemiological study; Primary aldosteronism; Prognosis; Surgical treatment; Medical treatment;

    机译:全国流行病学研究;原发性醛固酮增多症;预后手术治疗;药物治疗;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号